Minjuvi™ Inj. 200mg

Ingredient

One vial of powder contains 200 mg of tafasitamab

Content

White to slightly yellowish lyophilised powder.

Indication

In combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).